RT Journal Article
SR Electronic
T1 Autism spectrum disorder trios from consanguineous populations are enriched for rare biallelic variants, identifying 32 new candidate genes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.24.21268340
DO 10.1101/2021.12.24.21268340
A1 Harripaul, Ricardo
A1 Rabia, Ansa
A1 Vasli, Nasim
A1 Mikhailov, Anna
A1 Rodrigues, Ashlyn
A1 Pastore, Stephen F.
A1 Muhammad, Tahir
A1 Madanogopal, Thulasi
A1 Hashmi, Aisha
A1 Tran, Clinton
A1 Stan, Cassandra
A1 Aw, Katherine
A1 Azam, Maleeha
A1 Mahmood, Saqib
A1 Heidari, Abolfazl
A1 Qamar, Raheel
A1 French, Leon
A1 Tripathy, Shreejoy
A1 Agha, Zehra
A1 Iqbal, Muhammed
A1 Ghadami, Majid
A1 Santangelo, Susan
A1 Bozorgmehr, Bita
A1 Ayadhi, Laila Al
A1 Sasanfar, Roksana
A1 Maqbool, Shazia
A1 Knowles, James A.
A1 Ayub, Muhammad
A1 Vincent, John B
YR 2021
UL http://medrxiv.org/content/early/2021/12/30/2021.12.24.21268340.abstract
AB Autism spectrum disorder (ASD) is a severe neurodevelopmental disorder that affects about 1 in 55 children worldwide and imposes enormous economic and socioemotional burden on families and communities. Genetic studies of ASD have identified de novo copy number variants (CNVs) and point mutations that contribute significantly to the genetic architecture of ASD, but the majority of these studies were conducted in outbred populations, which are not ideal for detecting autosomal recessive (AR) inheritance. However, several studies have investigated ASD genetics in consanguineous populations and point towards AR as an under-appreciated source of ASD variants. Here, we used trio whole exome sequencing (WES) to look for rare variants for ASD in 115 proband-mother-father trios from populations with high rates of consanguinity, namely Pakistan, Iran, and Saudi Arabia. In total, we report 87 candidate sequence variants, with 57% biallelic, 21% autosomal dominant/de novo, and the rest X-linked. 52% of the variants were loss of function (LoF) or putative LoF (splice site, stop loss) and 47% non-synonymous. Our analysis indicates an enrichment of previously identified and candidate AR genes. These include variants in genes previously reported for AR ASD and/or intellectual disability (ID), such as AGA, ASL, ASPA, BTN3A2, CC2D1A, DEAF1, HTRA2, KIF16B, LINS1, MADD, MED25, MTHFR, RSRC1, TECPR2, VPS13B, ZNF335, and 32 previously unreported candidates, including 15 LoF or splice variants, in genes such as DAGLA, EFCAB8, ENPP6, FAXDC2, ILDR2, PKD1L1, SCN10A, and SLC36A1. We also identified candidate biallelic exonic loss CNVs a number of trios, implicating genes including DNAH7 and DHRS4/DHRS4L2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Canadian Institutes of Health Research to JBV (#MOP-102758 and #PJT-156402), also a National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award to NV. RH was supported by a Peterborough K.M. Hunter Charitable Foundation Graduate Scholarship. AR and AH were supported by International Research Fellowship Program scholarships from the Pakistani Higher Education Commission. CS was supported by a Summer University Research Program award from the Institute of Medical Science, University of Toronto.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Research Ethics Board approval was received for this study through the Centre for Addiction and Mental Health (CAMH) and other institutional recruiting sites.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors